ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

FUM Futura Medical Plc

40.50
1.70 (4.38%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.70 4.38% 40.50 39.70 40.50 40.00 39.00 39.60 359,491 16:35:16
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -5.85M -0.0194 -20.62 120.28M

Futura Medical PLC Notice of Preliminary Results (8147R)

05/03/2019 7:02am

UK Regulatory


Futura Medical (LSE:FUM)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Futura Medical Charts.

TIDMFUM

RNS Number : 8147R

Futura Medical PLC

05 March 2019

Notice of Preliminary Results

05 March 2019

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, will announce its preliminary results for the year ended 31 December 2018 on Wednesday 10 April 2019.

James Barder, Chief Executive Officer, and Angela Hildreth, Finance Director/Chief Operating Officer, will host a presentation for analysts at 10am BST on the day of the results at the office of N+1 Singer at 1 Bartholomew Lane, London EC2N 2AX.

A copy of the announcement will be made available on the Futura Medical website and following the results meeting a webcast of the presentation to analysts will also be made available within the Investor Centre section of the site.

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

Nominated Adviser and Broker:

N+1 Singer

Aubrey Powell/ Ben Farrow (Corporate Finance)

Mia Gardner/ Tom Salvesen (Corporate Broking)

Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Ellie Blackwell

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144

Notes to editors:

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys(R) drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORKMGGFZDMGLZZ

(END) Dow Jones Newswires

March 05, 2019 02:02 ET (07:02 GMT)

1 Year Futura Medical Chart

1 Year Futura Medical Chart

1 Month Futura Medical Chart

1 Month Futura Medical Chart

Your Recent History

Delayed Upgrade Clock